The U.S. Food and Drug Administration is warning health care providers that biotin, also known as vitamin B7, can significantly interfere with certain lab tests, resulting in incorrect results that may go undetected. Used in hormone tests and tests for certain cardiac health markers such as troponin due to its ability to bond with specific proteins, biotin is also frequently found in multi-vitamins, prenatal vitamins and dietary supplements marketed for hair, nail and skin growth. FDA states that biotin in blood and other samples taken from patients who are ingesting high levels of the substance in dietary supplements can cause “significantly incorrect” test results, both falsely high and falsely low, depending on the test. The agency warns that it has seen an increase in the number of reported adverse events related to biotin interference with lab tests. FDA urges providers to talk to patients about any biotin supplements that may be taking and communicate to the lab conducting testing if a patient is taking biotin. For more, see the FDA Safety Communication. 

Headline
There are now 17,180 confirmed cases of cyclosporiasis in the U.S., the Centers for Disease Control and Prevention reported Aug. 25. At least 11,844 additional…
Headline
The Food and Drug Administration has approved a blood test for detecting Alzheimer’s by Roche and Eli Lilly, according to an announcement Aug. 24 by Roche. The…
Headline
There have been 15,716 confirmed cases of cyclosporiasis across 47 states, Washington, D.C., and Puerto Rico since May 1, the Centers for Disease Control and…
Blog
By Rani E. Snyder, President, The John A. Hartford Foundation and Dr. Chris DeRienzo, AHA Chief Physician Executive/President of AHA’s HRET As the U.S.…
Headline
The Department of Health and Human Services Aug. 14 announced that three health systems have signed the agency’s voluntary pledge related to hospital efforts…
Headline
The Centers for Disease Control and Prevention Aug. 11 released a health advisory on the risk of severe arboviral disease among patients receiving B-cell-…